AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35716850 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycaemic parameters
Number of subjects: 40
Study 34301649 — intervention group
Group type: EXPERIMENTAL
Intervention: XGBoost model
Number of subjects: 1177
Study 34301649 — intervention group
Group type: EXPERIMENTAL
Intervention: LASSO regression model
Number of subjects: 1177
Study 34301649 — intervention group
Group type: COMPARATOR
Intervention: GWTG-HF risk score model
Number of subjects: 1177
Study 34301649 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall in-hospital mortality
Number of subjects: 1177
Study 34369239 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone conduction hearing device with high maximum power output
Number of subjects: 16
Study 34369239 — intervention group
Group type: COMPARATOR
Intervention: Bone conduction hearing device with lower maximum power output
Number of subjects: 16
Study 34932713 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 cantilevers (3 bends)
Number of subjects: 80
Study 34932713 — intervention group
Group type: COMPARATOR
Intervention: Type 2 cantilevers (2 bends)
Number of subjects: 80
Study 34932713 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 cantilevers
Number of subjects: 80
Study 35219309 — intervention group
Group type: EXPERIMENTAL
Intervention: Call for life Uganda (C4LU) intervention
Number of subjects: 0
Study 35219309 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care
Number of subjects: 0
Study 32088296 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam (3 tablets, 625 mg each, orally twice daily for 4 weeks)
Number of subjects: 30
Study 32088296 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo, orally twice daily for 4 weeks)
Number of subjects: 30
Study 34242140 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff Leak Test (CLT) communicated to healthcare team
Number of subjects: 100
Study 34242140 — intervention group
Group type: COMPARATOR
Intervention: No communication of CLT results to healthcare team (control)
Number of subjects: 100
Study 34149030 — intervention group
Group type: EXPERIMENTAL
Intervention: muscle sealant
Number of subjects: 28
Study 34149030 — intervention group
Group type: EXPERIMENTAL
Intervention: fascia sealant
Number of subjects: 28
Study 34149030 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisseel sealant
Number of subjects: 28
Study 34149030 — intervention group
Group type: COMPARATOR
Intervention: unsealed control
Number of subjects: 28
Study 35425986 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Centered Advance Care Planning for Teens with Cancer (FACE‐TC); 3 weekly sessions
Number of subjects: 126
Study 35425986 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Centered Advance Care Planning for Teens with Cancer (FACE‐TC)
Number of subjects: 126
Study 35425986 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 126
Study 33661716 — intervention group
Group type: EXPERIMENTAL
Intervention: cPCV7
Number of subjects: 511
Study 33661716 — intervention group
Group type: COMPARATOR
Intervention: Control (licensed tetanus, diphtheria, and acellular pertussis vaccine)
Number of subjects: 511
Study 33661716 — intervention group
Group type: COMPARATOR
Intervention: Control (23-valent polysaccharide vaccine)
Number of subjects: 511
Study 32618958 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with PSCs (n = 73)
Number of subjects: 153
Study 32618958 — intervention group
Group type: EXPERIMENTAL
Intervention: Products used to manage PSCs
Number of subjects: 153
Study 35753838 — intervention group
Group type: COMPARATOR
Intervention: EV71 vaccine (separate administration)
Number of subjects: 680
Study 35753838 — intervention group
Group type: COMPARATOR
Intervention: MR vaccine (separate administration)
Number of subjects: 680
Study 34780558 — intervention group
Group type: EXPERIMENTAL
Intervention: On-target message (n = 73)
Number of subjects: 843
Study 34780558 — intervention group
Group type: COMPARATOR
Intervention: Off-target message (n = 98)
Number of subjects: 843
Study 34780558 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall performance of RAL
Number of subjects: 843
Study 33356449 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted delivery systems based on nanoparticles
Number of subjects: 0
Study 33356449 — intervention group
Group type: EXPERIMENTAL
Intervention: Various delivery routes (oral, intradermal, intravenous)
Number of subjects: 0
Study 34551495 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume of 4 ml/kg (group V1)
Number of subjects: 180
Study 34551495 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume of 5 ml/kg (group V2)
Number of subjects: 180
Study 34551495 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume of 7 ml/kg (group V3)
Number of subjects: 180
Study 32157435 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 141
Study 32157435 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group: placebo)
Number of subjects: 141
Study 36142043 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy purchase habits (measured by AFHC purchase scores) in female adolescents declaring body mass gain during the COVID-19 pandemic
Number of subjects: 1333
Study 36142043 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy purchase habits (measured by AFHC purchase scores) in female adolescents declaring physical activity decrease during the COVID-19 pandemic
Number of subjects: 1333
Study 36142043 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy consumption habits (measured by AFHC consumption scores) in male adolescents declaring physical activity increase during the COVID-19 pandemic
Number of subjects: 1333
Study 36142043 — intervention group
Group type: EXPERIMENTAL
Intervention: General food habits
Number of subjects: 1333
Study 36142043 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass changes associated with food habits during the COVID-19 pandemic
Number of subjects: 1333
Study 34860040 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized measurement protocols combined with importance sampling
Number of subjects: 0
Study 34860040 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical techniques of machine learning and tensor networks
Number of subjects: 0
Study 34860040 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation of purity of product states and GHZ states
Number of subjects: 0
Study 35708779 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified coronally advanced tunnel technique (MCAT)
Number of subjects: 50
Study 35708779 — intervention group
Group type: EXPERIMENTAL
Intervention: Free gingival grafts (FGG)
Number of subjects: 50
Study 35140163 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined online mindfulness-based stress reduction (MBSR) and exercise programme (MOVE-Online), 2 hours MBSR and 1 hour exercise once a week for 8 weeks.
Number of subjects: 75
Study 35140163 — intervention group
Group type: COMPARATOR
Intervention: Online self-management guide, released biweekly with eight self-directed modules over 8 weeks.
Number of subjects: 75
Study 32189663 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine 0.2 µg/kg
Number of subjects: 120
Study 32189663 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine 0.4 µg/kg
Number of subjects: 120
Study 32189663 — intervention group
Group type: COMPARATOR
Intervention: Intravenous normal saline 10 mL (placebo)
Number of subjects: 120
Study 36442169 — intervention group
Group type: EXPERIMENTAL
Intervention: Online supervised exercise program
Number of subjects: 60
Study 36442169 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise program
Number of subjects: 60
Study 36442169 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 35288477 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.2 mg subcutaneous dose)
Number of subjects: 34
Study 35288477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 32887990 — intervention group
Group type: EXPERIMENTAL
Intervention: AS04-HPV-16/18 vaccine
Number of subjects: 0
Study 32276019 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital fluoroscopy (DF)
Number of subjects: 43
Study 32276019 — intervention group
Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 43
Study 34210600 — intervention group
Group type: EXPERIMENTAL
Intervention: White noise
Number of subjects: 66
Study 34210600 — intervention group
Group type: EXPERIMENTAL
Intervention: Lullabies
Number of subjects: 66
Study 34210600 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 66
Study 33258354 — intervention group
Group type: EXPERIMENTAL
Intervention: Flesh-moistening paste applied topically twice daily for eight weeks
Number of subjects: 50
Study 33258354 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied topically twice daily for eight weeks
Number of subjects: 50
Study 33258354 — intervention group
Group type: EXPERIMENTAL
Intervention: Flesh-moistening paste
Number of subjects: 50
Study 35220432 — intervention group
Group type: EXPERIMENTAL
Intervention: Management based on HyFoSy
Number of subjects: 1026
Study 35220432 — intervention group
Group type: COMPARATOR
Intervention: Management based on HSG
Number of subjects: 1026
Study 35220432 — intervention group
Group type: EXPERIMENTAL
Intervention: HyFoSy
Number of subjects: 1026
Study 35220432 — intervention group
Group type: COMPARATOR
Intervention: HSG
Number of subjects: 1026
Study 34330462 — intervention group
Group type: EXPERIMENTAL
Intervention: REPLENISH group (target protein 1.8-2.2 g/kg/day)
Number of subjects: 40
Study 34330462 — intervention group
Group type: COMPARATOR
Intervention: Standard group (target protein 0.8-1.0 g/kg/day)
Number of subjects: 40
Study 34330462 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 34330462 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometric and muscle strength measurements
Number of subjects: 40
Study 35643253 — intervention group
Group type: EXPERIMENTAL
Intervention: SABR to all metastases plus standard of care
Number of subjects: 99
Study 35643253 — intervention group
Group type: COMPARATOR
Intervention: Palliative standard-of-care treatment
Number of subjects: 99
Study 32409439 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 inhibitors
Number of subjects: 0
Study 33111455 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight (BMI ≥ 25–29.9 kg m−2)
Number of subjects: 525
Study 33111455 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (BMI ≥ 30 kg m−2)
Number of subjects: 525
Study 33111455 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined overweight and obesity
Number of subjects: 525
Study 33111455 — intervention group
Group type: EXPERIMENTAL
Intervention: Married women
Number of subjects: 525
Study 33111455 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aged 30–49 years
Number of subjects: 525
Study 33111455 — intervention group
Group type: EXPERIMENTAL
Intervention: Unemployed women
Number of subjects: 525
Study 33111455 — intervention group
Group type: EXPERIMENTAL
Intervention: Women from wealthier households
Number of subjects: 525
Study 33275769 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term maintenance rituximab (375 mg/m2 every 2 months, 4 administrations; n = 82)
Number of subjects: 270
Study 33275769 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term maintenance rituximab (375 mg/m2 every 2 months, up to 5 years; n = 83)
Number of subjects: 270
Study 33275769 — intervention group
Group type: COMPARATOR
Intervention: Short-term maintenance rituximab
Number of subjects: 270
Study 33275769 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term maintenance rituximab
Number of subjects: 270
Study 33275769 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic patients in need of immediate treatment
Number of subjects: 270
Study 33773059 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Glove (50 minutes per day, 5 days per week for 8 weeks)
Number of subjects: 20
Study 33773059 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Glove
Number of subjects: 20
Study 34215241 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese version of the entrapment scale (ES)
Number of subjects: 304
Study 36269726 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal previous cervical smear (Group 1)
Number of subjects: 360
Study 36269726 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade cervical dysplasia (H-SIL) at previous cervical smear (Group 2)
Number of subjects: 360
Study 36269726 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive women (Group 3)
Number of subjects: 360
Study 36269726 — intervention group
Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 360
Study 33637548 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP)
Number of subjects: 267
Study 33637548 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional placebo (CP)
Number of subjects: 267
Study 33637548 — intervention group
Group type: COMPARATOR
Intervention: No treatment (observational control)
Number of subjects: 267
Study 35452194 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone (BUP-NX)
Number of subjects: 570
Study 35452194 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 570
Study 35452194 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/severe depression (HDRS ≥ 17)
Number of subjects: 570
Study 35452194 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild depression (8 ≤ HDRS ≤ 16)
Number of subjects: 570
Study 35452194 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission at week 4
Number of subjects: 570
Study 34078103 — intervention group
Group type: COMPARATOR
Intervention: No WML
Number of subjects: 3180
Study 34078103 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild WML
Number of subjects: 3180
Study 34078103 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to Severe WML
Number of subjects: 3180
Study 34078103 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing WML grades
Number of subjects: 3180
Study 36317847 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior-stabilized (PS) implant
Number of subjects: 75
Study 36317847 — intervention group
Group type: EXPERIMENTAL
Intervention: Cruciate-retaining (CR) implant
Number of subjects: 75
Study 36317847 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial-stabilized (MS) implant
Number of subjects: 75
Study 32851588 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep efficiency less than 85%
Number of subjects: 1308
Study 32851588 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal awakening
Number of subjects: 1308
Study 32851588 — intervention group
Group type: EXPERIMENTAL
Intervention: Getting up to use the bathroom
Number of subjects: 1308
Study 32851588 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of sleep medication
Number of subjects: 1308
Study 33079965 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 74
Study 33079965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 36333935 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health app video consultations
Number of subjects: 52
Study 36333935 — intervention group
Group type: COMPARATOR
Intervention: Conventional face-to-face consultations
Number of subjects: 52
Study 34293372 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed formula (EHF)
Number of subjects: 73
Study 34293372 — intervention group
Group type: COMPARATOR
Intervention: Conventional formula (Control)
Number of subjects: 73
Study 34293372 — intervention group
Group type: EXPERIMENTAL
Intervention: EHF
Number of subjects: 73
Study 34293372 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 73
Study 33141833 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone calls
Number of subjects: 1542
Study 33141833 — intervention group
Group type: COMPARATOR
Intervention: Text messages (SMS)
Number of subjects: 1542
Study 33141833 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 1542
Study 33684639 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stabilization exercise program (CSEP)
Number of subjects: 21
Study 33684639 — intervention group
Group type: COMPARATOR
Intervention: Physical activity counseling
Number of subjects: 21
Study 32658428 — intervention group
Group type: EXPERIMENTAL
Intervention: AK124776 in recurrent group
Number of subjects: 60
Study 32658428 — intervention group
Group type: EXPERIMENTAL
Intervention: RP11-160A10.2 in recurrent group
Number of subjects: 60
Study 32658428 — intervention group
Group type: COMPARATOR
Intervention: AK124776
Number of subjects: 60
Study 32658428 — intervention group
Group type: COMPARATOR
Intervention: RP11-160A10.2
Number of subjects: 60
Study 36462782 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral extra-articular procedures (LEAPs) performed concomitant to anterior cruciate ligament reconstruction
Number of subjects: 0
Study 36462782 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Lemaire technique added to anterior cruciate ligament reconstruction
Number of subjects: 0
Study 36462782 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliotibial band based technique
Number of subjects: 0
Study 36462782 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory studies on iliotibial band based procedures
Number of subjects: 0
Study 32434237 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate combined with levobupivacaine periarticular cocktail (20 mL of magnesium sulfate 250 mg + levobupivacaine 50 mg + triamcinolone 25 mg + 0.9% normal saline)
Number of subjects: 60
Study 32434237 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine periarticular cocktail (20 mL of levobupivacaine 50 mg + triamcinolone 25 mg + 0.9% normal saline)
Number of subjects: 60
Study 33406735 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA + TEAS
Number of subjects: 71
Study 33406735 — intervention group
Group type: COMPARATOR
Intervention: PCA + sham-TEAS
Number of subjects: 71
Study 33406735 — intervention group
Group type: COMPARATOR
Intervention: PCA only
Number of subjects: 71
Study 33020647 — intervention group
Group type: EXPERIMENTAL
Intervention: LV20.19 CAR T cells (2.5 × 106 cells per kg)
Number of subjects: 22
Study 33020647 — intervention group
Group type: EXPERIMENTAL
Intervention: LV20.19 CAR T cells (various doses)
Number of subjects: 22
Study 34384345 — intervention group
Group type: COMPARATOR
Intervention: Resisted training
Number of subjects: 56
Study 34384345 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 34384345 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 56
Study 33758158 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased Bacteroides fragilis
Number of subjects: 402
Study 33758158 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylacetylglutamine
Number of subjects: 402
Study 32753113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 32753113 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (bolus 10 mg kg−1)
Number of subjects: 200
Study 32753113 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose + maintenance (bolus 10 mg kg−1 + maintenance 1 mg kg−1 hr−1)
Number of subjects: 200
Study 32753113 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (bolus 30 mg kg−1)
Number of subjects: 200
Study 32753113 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose + maintenance (bolus 30 mg kg−1 + maintenance 3 mg kg−1 hr−1)
Number of subjects: 200
Study 32572490 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRO smartphone app for RA (RA App v.1.0) with daily notifications regarding ePROs
Number of subjects: 78
Study 35352593 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone 300 mg/day
Number of subjects: 9
Study 35352593 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone 600 mg/day
Number of subjects: 9
Study 35352593 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone (both dosages)
Number of subjects: 9
Study 33712644 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (22.4 kHz)
Number of subjects: 0
Study 33712644 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 0
Study 32022106 — intervention group
Group type: EXPERIMENTAL
Intervention: Vida Ativa Melhorando a Saúde
Number of subjects: 90
Study 32022106 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 35289182 — intervention group
Group type: EXPERIMENTAL
Intervention: Time in target range (TTR) for systolic blood pressure (SBP) defined as 110 to 130 mm Hg
Number of subjects: 0
Study 35289182 — intervention group
Group type: EXPERIMENTAL
Intervention: TTR groups
Number of subjects: 0
Study 34057796 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel point-of-care lateral flow diagnostic test for detecting bacterial proteases
Number of subjects: 266
Study 34402044 — intervention group
Group type: EXPERIMENTAL
Intervention: Facemask oxygen (15 l.min-1)
Number of subjects: 84
Study 34402044 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen (50 l.min-1)
Number of subjects: 84
Study 34402044 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen plus mouthpiece (50 l.min-1 + 15 l.min-1)
Number of subjects: 84
Study 33905536 — intervention group
Group type: EXPERIMENTAL
Intervention: CIM consultation plus information leaflet
Number of subjects: 291
Study 33357789 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender equality-based reproductive health education
Number of subjects: 135
Study 33357789 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 135
Study 35050518 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth Empowerment Solutions (YES) program
Number of subjects: 329
Study 34083328 — intervention group
Group type: EXPERIMENTAL
Intervention: Demonstrate and distribute OraQuick HIV self-testing kits (HIVST)
Number of subjects: 6909
Study 34083328 — intervention group
Group type: EXPERIMENTAL
Intervention: Perform pinprick HIV testing (H2H)
Number of subjects: 6909
Study 34083328 — intervention group
Group type: EXPERIMENTAL
Intervention: Offer a choice to either receive HIVST or H2H
Number of subjects: 6909
Study 34083328 — intervention group
Group type: COMPARATOR
Intervention: Standard care (nurses counsel and refer to health facilities)
Number of subjects: 6909